LFST Stock Price, LifeStance Health Group, . Quote, Chart

Market Summary

USD7.39+0.02

Delayed

0.27%

LFST Alerts

Big jump in Earnings (Y/Y)

Losses in recent quarter

LFST Stock Price

View Fullscreen

LFST RSI Chart

LFST Valuation

Market Cap

2.8B

Price/Earnings (Trailing)

-16.32

Price/Sales (Trailing)

2.56

EV/EBITDA

-36.78

Price/Free Cashflow

-41.11

LFST Price/Sales (Trailing)

LFST Profitability

EBT Margin

-17.13%

Return on Equity

-12.11%

Return on Assets

-8.22%

Free Cashflow Yield

-2.43%

LFST Fundamentals

LFST Revenue

Revenue (TTM)

1.1B

Rev. Growth (Yr)

18.94%

Rev. Growth (Qtr)

7.07%

LFST Earnings

Earnings (TTM)

-173.1M

Earnings Growth (Yr)

38.39%

Earnings Growth (Qtr)

53.08%

Breaking Down LFST Revenue

Last 7 days

7.7%

Last 30 days

29.9%

Last 90 days

11.6%

Trailing 12 Months

-10.2%

How does LFST drawdown profile look like?

LFST Financial Health

Current Ratio

1.18

Debt/Equity

0.2

Debt/Cashflow

-0.11

LFST Investor Care

Shares Dilution (1Y)

1.47%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	1.1B	0	0	0
2023	909.0M	959.1M	1.0B	1.1B
2022	727.5M	776.5M	820.2M	859.5M
2021	408.7M	523.8M	595.6M	667.5M
2020	0	253.7M	336.0M	377.2M
2019	0	0	0	212.5M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of LifeStance Health Group, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 01, 2024	mullins kevin michael	sold	-57,449	5.93	-9,688	chief development officer
Apr 01, 2024	pantaleoni pablo	sold	-59,987	5.93	-10,116	chief digital officer
Apr 01, 2024	qureshi danish j.	sold	-76,882	5.93	-12,965	see remarks
Apr 01, 2024	pardo ryan	sold	-58,291	5.93	-9,830	see remarks
Mar 15, 2024	burdick kenneth a	sold	-1,347,720	6.28	-214,605	chief executive officer
Mar 14, 2024	pardo ryan	sold	-249,301	6.33	-39,384	see remarks
Mar 14, 2024	mullins kevin michael	sold	-281,938	6.33	-44,540	chief development officer
Mar 13, 2024	qureshi danish j.	sold	-972,920	6.32	-153,943	see remarks
Mar 12, 2024	pantaleoni pablo	sold	-292,735	6.76	-43,304	chief digital officer
Mar 11, 2024	cipollone paula	sold	-96,992	6.93	-13,996	see remarks

Which funds bought or sold LFST recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	added	13.01	-72,656	590,827	-%
May 16, 2024	JANE STREET GROUP, LLC	added	106	248,873	643,747	-%
May 16, 2024	COMERICA BANK	reduced	-88.16	-11,395	1,172	-%
May 15, 2024	VOLORIDGE INVESTMENT MANAGEMENT, LLC	new	-	1,891,230	1,891,230	0.01%
May 15, 2024	NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO	sold off	-100	-2,905	-	-%
May 15, 2024	TWO SIGMA INVESTMENTS, LP	added	124	425,193	975,415	-%
May 15, 2024	OCCUDO QUANTITATIVE STRATEGIES LP	reduced	-82.02	-512,601	84,609	0.01%
May 15, 2024	Tower Research Capital LLC (TRC)	reduced	-92.55	-176,599	11,008	-%
May 15, 2024	Cubist Systematic Strategies, LLC	new	-	420,244	420,244	-%
May 15, 2024	MARSHALL WACE, LLP	new	-	754,240	754,240	-%

Are Funds Buying or Selling LFST?

Are funds buying LFST calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own LFST

No. of Funds

Unveiling LifeStance Health Group, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 12, 2024	fmr llc	-	0	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Jan 24, 2024	lester michael k.	4.2%	15,953,887	SC 13G/A
Feb 13, 2023	lester michael k.	5.3%	19,993,012	SC 13G/A
Feb 09, 2023	fmr llc	-	0	SC 13G/A
Apr 11, 2022	fmr llc	-	0	SC 13G/A
Feb 14, 2022	silversmith partners i gp, llc	5.2%	19,541,192	SC 13G
Feb 11, 2022	tpg gp a, llc	46.8%	175,284,635	SC 13G
Feb 09, 2022	fmr llc	-	0	SC 13G
Feb 04, 2022	summit partners l p	12.22%	45,734,703	SC 13G

Recent SEC filings of LifeStance Health Group, Inc.

View All Filings

Date Filed	Form Type	Document
May 14, 2024	4	Insider Trading
May 13, 2024	144	Notice of Insider Sale Intent
May 10, 2024	144	Notice of Insider Sale Intent
May 09, 2024	10-Q	Quarterly Report
May 09, 2024	8-K	Current Report
May 07, 2024	144	Notice of Insider Sale Intent
Apr 23, 2024	ARS	ARS
Apr 23, 2024	DEF 14A	DEF 14A
Apr 23, 2024	DEFA14A	DEFA14A
Apr 19, 2024	4	Insider Trading

Peers (Alternatives to LifeStance Health Group, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
UNH	482.9B	379.5B	9.53%	9.48%	31.44	1.27	12.96%	-25.81%
CI	96.2B	206.0B	-2.11%	32.08%	24.97	0.47	12.55%	-43.95%
HCA	84.6B	66.7B	3.80%	15.55%	15.46	1.27	9.59%	-4.59%
CVS	72.4B	360.9B	-15.92%	-16.78%	9.89	0.2	9.07%	78.49%
CNC	41.7B	155.5B	8.44%	18.66%	15.24	0.27	6.34%	84.42%
DVA	12.3B	12.3B	9.53%	38.52%	15.03	0.99	5.77%	58.74%
UHS	11.9B	14.7B	11.04%	30.82%	14.63	0.81	7.99%	19.23%
MID-CAP
CHE	8.5B	2.3B	-6.47%	5.37%	30.15	3.73	5.96%	18.29%
ACHC	6.2B	3.0B	-5.49%	-7.73%	-545.12	2.06	10.92%	-104.06%
AMEH	2.3B	1.5B	9.06%	20.53%	36.62	1.57	19.34%	40.15%
AMN	2.2B	3.5B	4.01%	-38.44%	15.49	0.64	-27.67%	-62.43%
SMALL-CAP
ADUS	1.8B	1.1B	14.53%	25.72%	27.59	1.67	11.45%	30.74%
BKD	1.3B	3.0B	6.97%	85.25%	-7.66	0.44	4.98%	4.88%
BEAT	54.5M	-	-4.17%	-6.33%	-3.61	-	-	-1.05%
AMS	22.0M	21.6M	16.05%	23.93%	39.79	1.02	9.04%	-50.63%

LifeStance Health Group, Inc. News

Latest updates

LifeStance Health Group, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q2	2019Q4
Revenue	7.1%	300,437,000	280,603,000	262,895,000	259,578,000	252,589,000	229,360,000	217,560,000	209,527,000	203,095,000	189,995,000	173,835,000	160,549,000	143,132,000	118,121,000	101,982,000	45,453,000	111,661,000	-
Operating Expenses	1.4%	317,209,000	312,874,000	337,252,000	307,991,000	286,682,000	275,372,000	256,399,000	269,999,000	267,946,000	303,754,000	298,503,000	207,594,000	144,013,000	114,175,000	99,291,000	45,349,000	102,966,000	-
S&GA Expenses	-4.7%	88,934,000	93,368,000	130,945,000	101,854,000	84,626,000	89,817,000	81,248,000	103,559,000	103,369,000	152,652,000	162,943,000	85,479,000	32,651,000	23,665,000	19,534,000	8,642,000	20,854,000	-
EBITDA Margin	24.3%	-0.08	-0.10	-0.12	-0.10	-0.12	-0.17	-0.26	-0.39	-0.41	-0.36	-0.22	-0.01	-	-	-	-	-	-
Interest Expenses	6.7%	5,903,000	5,532,000	5,477,000	5,119,000	5,092,000	5,165,000	4,189,000	7,133,000	3,441,000	3,602,000	3,503,000	23,174,000	8,632,000	7,129,000	6,421,000	5,562,000	3,020,000	-
Income Taxes	-94.5%	363,000	6,643,000	-16,385,000	-6,542,000	-4,037,000	-7,060,000	-4,353,000	923,000	-6,676,000	-10,608,000	-8,751,000	-3,788,000	-2,761,000	-2,948,000	-1,074,000	1,370,000	-2,319,000	-
Earnings Before Taxes	45.9%	-20,734,000	-38,316,000	-77,968,000	-52,020,000	-38,279,000	-53,716,000	-42,206,000	-67,804,000	-69,004,000	-118,638,000	-129,203,000	-73,821,000	-11,443,000	-7,067,000	-4,368,000	-5,712,000	-27,264,000	-
EBT Margin	12.5%	-0.17	-0.20	-0.22	-0.19	-0.22	-0.27	-0.36	-0.50	-0.54	-0.50	-0.37	-0.18	-	-	-	-	-	-
Net Income	53.1%	-21,097,000	-44,959,000	-61,583,000	-45,478,000	-34,242,000	-46,656,000	-37,853,000	-68,727,000	-62,328,000	-108,030,000	-120,452,000	-70,033,000	-8,682,000	-5,489,000	-3,294,000	-4,342,000	-24,945,000	-
Net Income Margin	11.1%	-0.16	-0.18	-0.19	-0.17	-0.21	-0.25	-0.34	-0.46	-0.50	-0.46	-0.34	-0.17	-	-	-	-	-	-
Free Cashflow	-600.7%	-26,942,000	5,381,000	-35,151,000	-12,015,000	-15,619,000	25,534,000	-9,366,000	-18,032,000	-24,602,000	-8,042,000	-38,221,000	-37,637,000	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet													(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2020Q4
Assets	-0.2%	2,106	2,110	2,175	2,171	2,159	2,174	1,980	1,969	1,958	1,927	1,915	1,914	1,570
Current Assets	8.1%	244	226	264	238	213	233	253	244	263	267	328	364	76.00
Cash Equivalents	-37.3%	49.00	79.00	43.00	80.00	68.00	109	90.00	97.00	114	148	212	276	19.00
Net PPE	-3.1%	182	188	190	193	194	194	193	191	171	152	115	92.00	59.00
Goodwill	0%	1,293	1,293	1,293	1,294	1,294	1,273	1,250	1,244	1,229	1,205	1,160	1,139	1,099
Liabilities	-0.5%	677	681	720	676	653	655	448	437	416	382	370	370	537
Current Liabilities	2.3%	207	203	241	181	181	176	112	112	126	117	105	113	76.00
Long Term Debt	-0.1%	280	280	248	249	225	225	212	203	177	157	157	157	363
LT Debt, Non Current	-100.0%	-	280	248	249	225	225	212	203	177	157	157	157	363
Shareholder's Equity	0.0%	1,429	1,429	1,455	1,495	1,505	1,519	1,532	1,531	1,543	1,545	1,545	1,545	998
Retained Earnings	-2.8%	-781	-760	-715	-654	-608	-572	-525	-488	-419	-357	-249	-128	-13.12
Additional Paid-In Capital	0.9%	2,204	2,184	2,163	2,141	2,108	2,084	2,051	2,016	1,958	1,898	1,790	1,669	1.00
Shares Outstanding	0.9%	382	379	379	378	377	376	376	376	374	374	374	374	-
Float	-	-	-	-	965	-	-	-	405	-	-	-	1,996	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																		(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q2	2019Q4
Cashflow From Operations	-230.0%	-21,838	16,795	-25,355	-434	-7,890	35,918	5,730	7,833	3,308	30,635	-14,209	-16,915	9,909	4,160	11,188	-37,317	13,436	-
Share Based Compensation	-1.6%	20,581	20,919	21,525	33,078	23,866	35,195	34,870	57,510	59,855	108,630	120,689	29,515	605	587	573	292	-	-
Cashflow From Investing	55.3%	-5,104	-11,414	-9,796	-11,581	-27,549	-30,296	-20,272	-38,038	-50,855	-79,562	-43,585	-59,094	-11,835	-144,644	-20,234	-671,213	-25,078	-
Cashflow From Financing	-107.9%	-2,431	30,838	-1,849	23,326	-4,888	12,663	8,192	12,901	13,508	-15,167	-6,270	312,702	22,591	134,245	20,310	722,334	35,385	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

LFST Income Statement

2024-03-31

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
TOTAL REVENUE	$ 300,437	$ 252,589
OPERATING EXPENSES
Center costs, excluding depreciation and amortization shown separately below	205,711	182,987
General and administrative expenses	88,934	84,626
Depreciation and amortization	22,564	19,069
Total operating expenses	317,209	286,682
LOSS FROM OPERATIONS	(16,772)	(34,093)
OTHER EXPENSE
Gain on remeasurement of contingent consideration	2,015	1,037
Transaction costs	0	(86)
Interest expense, net	(5,903)	(5,092)
Other expense	(74)	(45)
Total other expense	(3,962)	(4,186)
LOSS BEFORE INCOME TAXES	(20,734)	(38,279)
INCOME TAX (PROVISION) BENEFIT	(363)	4,037
NET LOSS	$ (21,097)	$ (34,242)
NET LOSS PER SHARE, BASIC	$ (0.06)	$ (0.09)
NET LOSS PER SHARE, DILUTED	$ (0.06)	$ (0.09)
Weighted-average shares used to compute basic net loss per share	376,331	360,902
Weighted-average shares used to compute diluted net loss per share	376,331	360,902
Net Income (Loss)	$ (21,097)	$ (34,242)
OTHER COMPREHENSIVE (LOSS)
Unrealized gains (losses) on cash flow hedge, net of tax	583	(1,270)
COMPREHENSIVE LOSS	$ (20,514)	$ (35,512)

LFST Balance Sheet

2024-03-31

CONSOLIDATED BALANCE SHEETS (unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
CURRENT ASSETS
Cash and cash equivalents	$ 49,451	$ 78,824
Patient accounts receivable, net	175,937	125,405
Prepaid expenses and other current assets	18,729	21,502
Total current assets	244,117	225,731
NONCURRENT ASSETS
Property and equipment, net	182,428	188,222
Right-of-use assets	165,845	170,703
Intangible assets, net	208,529	221,072
Goodwill	1,293,346	1,293,346
Other noncurrent assets	12,051	10,895
Total noncurrent assets	1,862,199	1,884,238
Total assets	2,106,316	2,109,969
CURRENT LIABILITIES
Accounts payable	11,938	7,051
Accrued payroll expenses	100,432	102,478
Other accrued expenses	37,272	35,012
Contingent consideration	4,454	8,169
Operating lease liabilities, current	49,729	46,475
Other current liabilities	3,639	3,688
Total current liabilities	207,464	202,873
NONCURRENT LIABILITIES
Long-term debt, net	279,870	280,285
Operating lease liabilities, noncurrent	173,255	181,357
Deferred tax liability, net	15,970	15,572
Other noncurrent liabilities	760	952
Total noncurrent liabilities	469,855	478,166
Total liabilities	677,319	681,039
COMMITMENTS AND CONTINGENCIES (see Note 12)
STOCKHOLDERS' EQUITY
Preferred stock - par value $0.01 per share; 25,000 shares authorized as of March 31,2024 and December 31, 2023; 0 shares issued and outstanding as of March 31, 2024 and December 31,2023	0	0
Common stock - par value $0.01 per share 800,000 shares authorized as of March 31,2024 and December 31, 2023 ; 378,725 and 378,725 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	3,821	3,789
Additional paid-in capital	2,204,233	2,183,684
Accumulated other comprehensive income	2,886	2,303
Accumulated deficit	(781,943)	(760,846)
Total stockholders' equity	1,428,997	1,428,930
Total liabilities and stockholders' equity	$ 2,106,316	$ 2,109,969

About LifeStance Health Group, Inc.

LifeStance Health Group, Inc., through its subsidiaries, provides outpatient mental health services. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy. It treats a range of mental health conditions, including anxiety, depression, bipolar disorder, eating disorders, psychotic disorders, and post-traumatic stress disorder. In addition, the company operates outpatient mental health platform, as well as offers patients care virtually through its online delivery platform or in-person at its centers in 33 states. It serves children, adolescents, adults, and geriatrics. LifeStance Health Group, Inc. was founded in 2017 and is based in Scottsdale, Arizona.

CEO	Mr. Kenneth Alan Burdick
WEBSITE	lifestance.com
INDUSTRY	Healthcare Plans
EMPLOYEES	6132

LifeStance Health Group, Inc. Frequently Asked Questions

What is the ticker symbol for LifeStance Health Group, Inc.? What does LFST stand for in stocks?

LFST is the stock ticker symbol of LifeStance Health Group, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of LifeStance Health Group, Inc. (LFST)?

As of Fri May 17 2024, market cap of LifeStance Health Group, Inc. is 2.83 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of LFST stock?

You can check LFST's fair value in chart for subscribers.

What is the fair value of LFST stock?

You can check LFST's fair value in chart for subscribers. The fair value of LifeStance Health Group, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of LifeStance Health Group, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for LFST so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is LifeStance Health Group, Inc. a good stock to buy?

The fair value guage provides a quick view whether LFST is over valued or under valued. Whether LifeStance Health Group, Inc. is cheap or expensive depends on the assumptions which impact LifeStance Health Group, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for LFST.

What is LifeStance Health Group, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, LFST's PE ratio (Price to Earnings) is -16.32 and Price to Sales (PS) ratio is 2.56. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. LFST PE ratio will change depending on the future growth rate expectations of investors.